TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir.L12045 It is being investigated for use in HIV-1 infections. TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for both treatment-naive and PI-experienced patients.L12045,A191643
TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.L12012
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Alprazolam | The serum concentration of Alprazolam can be increased when it is combined with TMC-310911. |
| Cisapride | The serum concentration of Cisapride can be increased when it is combined with TMC-310911. |
| Clarithromycin | The serum concentration of Clarithromycin can be increased when it is combined with TMC-310911. |
| Cyclophosphamide | The serum concentration of the active metabolites of Cyclophosphamide can be increased when Cyclophosphamide is used in combination with TMC-310911. |
| Garlic | Garlic can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rubella virus vaccine | The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with TMC-310911. |
| Varicella zoster vaccine (live/attenuated) | The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with TMC-310911. |
| Bacillus calmette-guerin substrain tice live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with TMC-310911. |
| Bacillus calmette-guerin substrain connaught live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TMC-310911. |
| Yellow fever vaccine | The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with TMC-310911. |
| Anthrax vaccine | The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with TMC-310911. |
| Typhoid Vaccine Live | The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with TMC-310911. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with TMC-310911. |
| Human adenovirus e serotype 4 strain cl-68578 antigen | The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with TMC-310911. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with TMC-310911. |
| Adenovirus type 7 vaccine live | The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with TMC-310911. |
| Bacillus calmette-guerin substrain russian BCG-I live antigen | The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with TMC-310911. |
| Pitavastatin | The serum concentration of Pitavastatin can be decreased when it is combined with TMC-310911. |
| Pantoprazole | Pantoprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Omeprazole | Omeprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lansoprazole | Lansoprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cimetidine | Cimetidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nizatidine | Nizatidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Esomeprazole | Esomeprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ranitidine | Ranitidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Famotidine | Famotidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methantheline | Methantheline can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rabeprazole | Rabeprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium | Aluminium can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium bicarbonate | Sodium bicarbonate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexlansoprazole | Dexlansoprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium carbonate | Calcium carbonate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Metiamide | Metiamide can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Roxatidine acetate | Roxatidine acetate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lafutidine | Lafutidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lavoltidine | Lavoltidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bismuth subnitrate | Bismuth subnitrate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium acetoacetate | Aluminium acetoacetate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium peroxide | Magnesium peroxide can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Almasilate | Almasilate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium glycinate | Aluminium glycinate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aloglutamol | Aloglutamol can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Niperotidine | Niperotidine can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dexrabeprazole | Dexrabeprazole can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium silicate | Calcium silicate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium zirconium cyclosilicate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vonoprazan | Vonoprazan can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Amiodarone | The serum concentration of Amiodarone can be increased when it is combined with TMC-310911. |
| Carbamazepine | The serum concentration of TMC-310911 can be decreased when it is combined with Carbamazepine. |
| St. John's Wort | The serum concentration of TMC-310911 can be decreased when it is combined with St. John's Wort. |
| Bosentan | The serum concentration of Bosentan can be increased when it is combined with TMC-310911. |
| Rifapentine | The serum concentration of TMC-310911 can be decreased when it is combined with Rifapentine. |
| Elivaldogene autotemcel | The therapeutic efficacy of Elivaldogene autotemcel can be decreased when used in combination with TMC-310911. |
| Voriconazole | The serum concentration of Voriconazole can be increased when it is combined with TMC-310911. |
| Tegoprazan | Tegoprazan can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chikungunya vaccine (live, attenuated) | The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with TMC-310911. |
| Smallpox (Vaccinia) Vaccine, Live | The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with TMC-310911. |